drugset

drugset / Trial / NCT04723914

Dual Target CAR-T Cells in B-cell Lymphoma

NCT04723914 ↗

Phase 1/2 Unknown 20 enrolled YuLi

NaSingle-groupOpen-labelTreatment

Summary

Prospectively evaluate the safety and effectiveness of CD19/CD20 dual-target CAR-T cells in the treatment of relapsed/refractory B-cell lymphoma .

Timeline

Start: 2020-10-20
Primary completion: 2022-12-31
Completion: 2022-12-31

Publications

Wang L, Fang C, Zheng Y, Xu Y, Huang W, Zhao W, Wang Y, Xia J, Tan K, Wang L, Peng H, Guo X, Wang S, Wang L, Liu L, Qiao J, Meng X, He Z, Wen Z, Yu C, Mei J, Wang H, Li Y, Yu L. Clinical outcomes and spatial transcriptomic profiles of CD19/20 CAR-T therapy in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Immunother Cancer. 2026 May 17;14(5):e015114. doi: 10.1136/jitc-2026-015114.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CD19/20 CAR-T cells	Cell therapy	—	—

Indications